The NPCA team is pleased to announce the official launch of a Quality Improvement (QI) intervention in January 2026. The primary goal is to ensure men with hormone-sensitive metastatic prostate cancer are being treated with treatment intensification therapy where appropriate.
The intervention will be in three stages:
Outlier Process
Identify and provide feedback to potential negative outliers, addressing underlying issues, whether related to data submissions or clinical care.
Educational Webinars
- Evidence-based benefits of utilising treatment intensification
In collaboration with BURST, the NPCA hosted a webinar on “The use of systemic anti-cancer treatment in metastatic prostate cancer”
Webinar: The Use of SACT in Metastatic Prostate Cancer2. Optimal data collection and processing strategies
The NPCA hosted a webinar on “Improving Data Collection Quality and Completeness for Systemic Anti-Cancer Therapy (SACT) in Prostate Cancer”. Representatives from Royal Marsden NHS Foundation Trust and Lancashire and South Cumbria Cancer Alliance are invited to share their best practices.
Webinar: Improving Data Collection Quality and Completeness Case Study – Royal Marsden NHS Foundation TrustQuarterly Data Dashboard
Results will be added to the NPCA Data Dashboard, updated quarterly, with repeated assessments to track progress over time.
NPCA QI Intervention Poster